
The weight-loss drug semaglutide, sold under the names Ozempic and Wegovy, may do far more than shrink waistlines. Research suggests it could also shield the brain after traumatic injury.
A 2026 study published in Neural Regeneration Research by scientists at Beijing Tiantan Hospital, and available in the PubMed database, found that semaglutide reduced brain swelling, preserved the blood-brain barrier, and blocked dangerous inflammatory cascades in mice with traumatic brain injuries. “Our findings reveal the dual anti-inflammatory and neuroprotective roles of semaglutide, providing important preclinical evidence for its clinical application in the acute phase of traumatic brain injury,” the researchers wrote.
The possibilities are enormous. Last year, a University of Wisconsin–Madison retrospective study of more than two million stroke patients found that those taking semaglutide had a mortality rate of just 5.26%, compared with 21.61% for non-users.
While human clinical trials for TBI are still needed, scientists say GLP-1 drugs represent the most promising new avenue for brain injury treatment in decades.









